Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults:: focus on memantine

被引:97
作者
Wenk, Gary L.
Parsons, Chris G.
Danysz, Wojciech
机构
[1] Merz Pharmaceut, Preclin R&D, D-60318 Frankfurt, Germany
[2] Ohio State Univ, Dept Psychol & Neurosci, Columbus, OH 43210 USA
来源
BEHAVIOURAL PHARMACOLOGY | 2006年 / 17卷 / 5-6期
关键词
Alzheimer's disease; neurodegeneration; neuroprotection; N-methyl-D-aspartate receptor antagonist;
D O I
10.1097/00008877-200609000-00007
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Glutamatergic neurotransmission is critical to normal learning and memory and when the activity of glutamate neurons becomes excessive, or the normal function of its primary receptors becomes dysfunctional, this may lead to pathological changes associated with age-related neurodegenerative diseases. Anomalous glutamatergic activity associated with Alzheimer's disease may be due to a postsynaptic receptor and downstream defects that produce inappropriately timed or sustained glutamate activation of N-methyl-D-aspartate receptors, leading to neuronal injury and death and cognitive deficits associated with dementia. The mechanisms leading to the condition of chronically depolarized membranes on vulnerable neurons in the Alzheimer's disease brain are likely due to a complex interaction between oxidative stress, mitochondrial failure, chronic brain inflammation and the presence of amyloid-beta and hyperphosphorylated-tau; each of these factors are highly interrelated with each other and are discussed with an emphasis upon potential therapeutic mechanisms underlying the neuroprotective actions of memantine.
引用
收藏
页码:411 / 424
页数:14
相关论文
共 181 条
[31]   The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence [J].
Danysz, W ;
Parsons, CG .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 :S23-S32
[32]  
DANYSZ W, 1995, BEHAV PHARMACOL, V6, P455
[33]   Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies [J].
Danysz, W ;
Parsons, CG ;
Kornhuber, J ;
Schmidt, WJ ;
Quack, G .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (04) :455-468
[34]   GLUTAMATE ANTAGONISTS HAVE DIFFERENT EFFECTS ON SPONTANEOUS LOCOMOTOR-ACTIVITY IN RATS [J].
DANYSZ, W ;
ESSMANN, U ;
BRESINK, I ;
WILKE, R .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 48 (01) :111-118
[35]   ARE NMDA ANTAGONISTIC PROPERTIES RELEVANT FOR ANTIPARKINSONIAN-LIKE ACTIVITY IN RATS - CASE OF AMANTADINE AND MEMANTINE [J].
DANYSZ, W ;
GOSSEL, M ;
ZAJACZKOWSKI, W ;
DILL, D ;
QUACK, G .
JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1994, 7 (03) :155-166
[36]   Neuroprotective and symptomatological action of memantine relevant for alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action [J].
Danysz, Wojciech ;
Parsons, Chris G. ;
Moebius, Hans-Joerg ;
Stoeffler, Albrecht ;
Quack, Guenter .
NEUROTOXICITY RESEARCH, 2000, 2 (2-3) :85-97
[37]   Cholinergic markers in elderly patients with early signs of Alzheimer disease [J].
Davis, KL ;
Mohs, RC ;
Marin, D ;
Purohit, DP ;
Perl, DP ;
Lantz, M ;
Austin, G ;
Haroutunian, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (15) :1401-1406
[38]   In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors [J].
De Sarno, P ;
Bijur, GN ;
Zmijewska, AA ;
Li, XH ;
Jope, RS .
NEUROBIOLOGY OF AGING, 2006, 27 (03) :413-422
[39]   Amyloid suppresses induction of genes critical for memory consolidation in APP+PS1 transgenic mice [J].
Dickey, CA ;
Gordon, MN ;
Mason, JE ;
Wilson, NJ ;
Diamond, DM ;
Guzowski, JF ;
Morgan, D .
JOURNAL OF NEUROCHEMISTRY, 2004, 88 (02) :434-442
[40]   Microglial cell activation in aging and Alzheimer disease: Partial linkage with neurofibrillary tangle burden in the hippocampus [J].
DiPatre, PL ;
Gelman, BB .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) :143-149